
Two experimental drugs do not appear to slow memory loss or mental decline in patients in the early stages of a rare, inherited form of Alzheimer’s disease, according to initial results from a clinical trial. The international phase 2 and 3 clinical trial separately evaluated the two drugs — solanezumab (Eli Lilly and Co.), and… read on >